Article
Pharmacology & Pharmacy
Yuxin Liu, Si Chen, Yan Wang, Zeyang Zhang, Hui Zhang, Ziyi Wang, Ziyou Tao, Jianyao Wang, Peng Zhang
Summary: In this study, dexamethasone was found to promote apoptosis through the AKT-mTOR pathway for the treatment of thymoma-associated myasthenia gravis (MG). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, weighted gene co-expression network analysis (WGCNA), and molecular docking technology were used to identify targets and analyze the mechanism of action. The study provides theoretical support and new research perspectives for this disease.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2023)
Article
Clinical Neurology
Rodrigo Alvarez-Velasco, Gerardo Gutierrez-Gutierrez, Juan Carlos Trujillo, Elisabeth Martinez, Sonia Segovia, Marina Arribas-Velasco, Guillermo Fernandez, Carmen Paradas, Beatriz Velez-Gomez, Carlos Casasnovas, Velina Nedkova, Antonio Guerrero-Sola, Alba Ramos-Fransi, Alicia Martinez-Pineiro, Julio Pardo, Teresa Sevilla, Maria Teresa Gomez-Caravaca, Adolfo Lopez de Munain, Ivonne Jerico, Ana L. Pelayo-Negro, Maria Asuncion Martin, Yolanda Morgado, Maria Dolores Mendoza, Helena Perez-Perez, Ricard Rojas-Garcia, Janina Turon-Sans, Luis Querol, Eduard Gallardo, Isabel Illa, Elena Cortes-Vicente
Summary: The study on myasthenia gravis patients with thymoma found that they had more severe symptoms and worse prognosis compared to non-thymoma patients. Thymoma recurrence may lead to transient worsening, while patients with unresectable thymomas tend to present more severe forms of MG.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Oncology
Mingbo Tang, Yifeng Shao, Junxue Dong, Xinliang Gao, Shixiong Wei, Jianzun Ma, Yang Hong, Zhiqin Li, Taiyu Bi, Yipeng Yin, Wenyu Zhang, Wei Liu
Summary: This study used a meta-analysis to examine the incidence of postoperative myasthenia gravis (PMG) and risk factors in patients with non-MG thymoma. The results showed that the incidence of PMG in preoperative patients with non-MG thymoma was 8%. Preoperative seropositive acetylcholine receptor antibody, open thymectomy, non-R0 resection, WHO type B, and postoperative inflammation were identified as risk factors for PMG.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Shruti M. Raja, Jeffrey T. Guptill, Alec McConnell, Hussein R. Al-Khalidi, Matthew G. Hartwig, Jacob A. Klapper
Summary: This study examines the perioperative complications of open and minimally invasive thymectomy techniques in autoimmune myasthenia gravis patients. The findings suggest that minimally invasive and trans cervical thymectomies have lower odds of perioperative complications compared to transthoracic thymectomies in nonthymomatous MG cases.
ANNALS OF THORACIC SURGERY
(2022)
Article
Medicine, Research & Experimental
Zhu Haoshuai, Zou Jianyong, Yang Lei, Zeng Bo, Jiefei Xiao, Xin Zhang, Zhenguang Chen, Su Chunhua
Summary: In patients with thymomatous MG undergoing thymectomy, it takes on average 6 months to achieve a 3 point reduction in QMGS and 30 months for another 3 point reduction. Older age (>=42 years) and higher Masaoka-Koga stage (>I) are associated with a lower probability of achieving a reduction in QMGS.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Surgery
Ahmed AL-Bulushi, Issa Al Salmi, Fatma Al Rahbi, AbdulAziz Al Farsi, Suad Hannawi
Summary: This study investigated the epidemiology of patients with myasthenia gravis who underwent thymectomy at the Royal Hospital in Muscat, Oman over the past three decades. The results showed that post-thymectomy, most patients experienced significant clinical improvement, with a small percentage achieving complete clinical remission.
ASIAN JOURNAL OF SURGERY
(2021)
Review
Cell Biology
Cloe A. Payet, Axel You, Odessa-Maud Fayet, Nadine Dragin, Sonia Berrih-Aknin, Rozen Le Panse
Summary: Myasthenia gravis is a rare autoimmune disease associated with antibodies against components of the neuromuscular junction. An interferon type I signature is detected in the thymus of early-onset and thymoma-associated MG patients. IFN-I is normally produced in response to viral infection, but it is also present in some systemic autoimmune diseases known as interferonopathies.
Article
Oncology
Liu Chen, Yi Li, Xiaohua Dong, Guilong Tanzhu, Xianjing Chu, Fuxing Deng, Xiang Li, Jing Zhang, Bin Long, Di Jing, Lishui Niu, Haiqin Peng, Huan Yang, Rongrong Zhou
Summary: This study examined the impact of postoperative radiotherapy (PORT) on patients with thymoma associated with myasthenia gravis (MG). The results showed that PORT can improve MG symptoms and increase disease-free survival (DFS) and overall survival (OS) rates for these patients. The effect is particularly significant for patients with higher histologic subtype and Masaoka-Koga staging.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Medicine, General & Internal
Hongxi Chen, Lingyao Kong, Ying Zhang, Xue Lin, Ziyan Shi, Qin Du, Xiaofei Wang, Yanlin Lang, Linjun Cai, Zichao Mou, Wenqin Luo, Shuangjie Li, Hongyu Zhou
Summary: This study revealed the importance of monitoring myocardial injury biomarkers in patients with myasthenia gravis (MG) and identified age, infection, myasthenic crisis, thymoma, and immune checkpoint inhibitor therapy as independent risk factors for elevated troponin T (TnT) levels. High TnT levels, female sex, thymoma, and infection were identified as independent risk factors for death.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Genetics & Heredity
Jinman Zhuang, Maohao Guan, Maolin Liu, Yuhang Liu, Shuyan Yang, Zhijian Hu, Fancai Lai, Fei He
Summary: This study investigated the immune-related lncRNA profiles in thymoma patients with or without MG, identifying key expression and methylation differences. GO and KEGG pathway analyses revealed important pathways, providing insights for further research.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Eleonora Pardini, Federico Cucchiara, Sara Palumbo, Giulia Tarrini, Alessia Di Vita, Fabio Coppede, Vanessa Nicoli, Melania Guida, Michelangelo Maestri, Roberta Ricciardi, Vittorio Aprile, Marcello C. Ambrogi, Serena Barachini, Marco Lucchi, Iacopo Petrini
Summary: This study provides insights into the mutational landscape of thymic epithelial tumors, identifying recurrent mutations in the GTF2I gene and predicted inactivation of tumor suppressor genes. These findings contribute to a better understanding of the genetic basis of thymic epithelial tumors and may have implications for future research and treatment strategies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Clinical Neurology
Deepak Menon, Hans Katzberg, Carolina Barnett, Prodipto Pal, Andrea Bezjak, Shaf Keshavjee, Vera Bril
Summary: The World Health Organization pathological subtype of thymoma did not correlate with Myasthenia Gravis outcomes. However, positive acetylcholine antibody serology, presence of TFH, and non-recurrence of thymoma predict a favorable outcome.
Article
Clinical Neurology
Sohyeon Kim, Ki Hoon Kim, Hye Yoon Chung, Hyung Jun Park, Young-Chul Choi, Ha Young Shin, Seung Woo Kim
Summary: This study found that the presence of anti-titin antibodies was associated with myocarditis in patients with myasthenia gravis, while thymoma was not. Early suspicion of myocarditis may be necessary in myasthenia gravis patients with anti-titin antibodies.
JOURNAL OF NEUROLOGY
(2023)
Article
Biology
Ning Ding, Yu Zhang, Mengna Huang, Jianfeng Liu, Chonglong Wang, Chun Zhang, Jinkang Cao, Qin Zhang, Li Jiang
Summary: This study identified circ-CREBBP as a biomarker and therapeutic target for male reproductive diseases. It promotes sperm motility and inhibits apoptosis by sponging miR-10384 and miR-143-3p.
COMMUNICATIONS BIOLOGY
(2022)
Article
Clinical Neurology
Fuqiang Wang, Hanlu Zhang, Guanghao Qiu, Zhiyang Li, Yun Wang
Summary: This study investigated the ceRNA network and the relationship between immune cells in patients with thymoma and myasthenia gravis. The findings suggest that the LINC00452/miR-204/CHST4 axis may regulate thymic regulatory T cells in the development of myasthenia gravis.
FRONTIERS IN NEUROLOGY
(2022)